{"url_path":"/sec/sxtp/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 OTHER INFORMATION","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1946563/0001554855-26-001058-index.html","accession_number":"0001554855-26-001058","cik":"0001946563","ticker":"SXTP","issuer_name":"60 DEGREES PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1946563/0001554855-26-001058-index.html","primary_entity_key":"0001946563","primary_entity_name":"60 DEGREES PHARMACEUTICALS, INC."},"word_count":80,"has_tables":true,"body_markdown":"ITEM 5. OTHER INFORMATION\n\n \n\nSecurities Trading Plans\n\n \n\nDuring the three months ended March 31, 2026, none of our Section 16 officers or directors (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any “non-Rule 10b5-1 trading arrangement” (as defined in Section 408(c) of Regulation S-K).\n\n \n\n36"}